Vepesid prescribing information |
|
 |
|
2007 Dec;26(12):1339-43.
Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ.
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China. gzsunxf@yahoo.com.cn
[Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents] [Article in Chinese]
2007 Dec;73(15):1563-7. Epub 2007 Dec 11.
Lim S, Grassi J, Akhmedjanova V, Debiton E, Balansard G, Beliveau R, Barthomeuf C.
INSERM-484, Clermont-Ferrand, France.
Reversal of P-glycoprotein-mediated drug efflux by eudesmin from Haplophyllum perforatum and cytotoxicity pattern versus diphyllin, podophyllotoxin and etoposide.
2007 Jul-Sep;3(3):150-2.
Attili VS, Chandra RC, Anupama G, Loknath D, Bapsy PP, Dadhich HK, Babu GK.
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 029, India. sureshattili@yahoo.com
Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors.
BACKGROUND: In patients with small-volume disseminated disease of germ cell tumors, cure can be achieved with four cycles of bleomycin, etoposide, and cisplatin (BEP). However, around 20% of these cases are not curable. Strategies to improve cure rates have shown that none of the currently available modalities were superior to the others. Among the most used ones, BEP and VIP (etoposide, cisplatin, and ifosfamide) have been the most studied. However, there are no reports comparing the two, except for a few in abstract forms from southern India. Therefore, we did a treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs VIP) that are used in poor-prognosis metastatic germ cell tumors. MATERIALS AND METHODS: All male patients with germ cell tumors, diagnosed as having poor risk by IGCCCG, between January 2002 and December 2004 were included in the study. Clinical, laboratory, and other data were recorded. The patients were stratified into two categories on the basis of the type of chemotherapeutic regimen they received. RESULTS: In all, 46 patients were analyzed, with a median follow up of 26.6 months. The baseline characteristics (age, stage, PS, histology, and serum markers) were not different in the two treatment arms. There is no significant difference in the outcome with either of the chemotherapeutic modalities. VIP is less cost effective and more toxic compared to BEP. CONCLUSION: In view of the greater toxicity and cost of therapy, as well as lack of either overall or disease free survival advantage, VIP is not a preferred option for patients with high-risk germ cell tumors in the Indian setting and it is still advisable to treat patients with BEP.
Ann Oncol. 2008 Aug 5.
Kim BS, Kim DW, Im SA, Kim CW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK.
Department of Internal Medicine, Seoul Municipal Boramae Hospital, Seoul.
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone.
Clin Ther. 2008 Jul;30(7):1336-40.
André N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC.
Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone, Marseille, France.
Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
Int J Urol. 2008 Sep;15(9):851-3.
Tatokoro M, Kawakami S, Yonese J, Fujii Y, Okubo Y, Yamamoto S, Takeshita H, Komai Y, Ishikawa Y, Fukui I.
Department of Urology, Cancer Institute Hospital, Tokyo, Japan.
Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.
Thorax. 2008 Sep 11.
Lee SM, James L, Qian W, Spiro S, Eisen T, Gower N, Ferry D, Gilligan D, Harper P, Prendiville J, Hocking M, Rudd R.
University College London Hospitals, United Kingdom.
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.
Bone Marrow Transplant. 2008 Sep 15.
Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S, Dean R, Koo A, Chan J, Sweetenham J, Bolwell B.
Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
J Clin Oncol. 2008 Sep 20;26(27):4385-93.
Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Interg
Department of PaediatricHaematology/Oncology, University Children's Hospital Münster, Switzerland.
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Bone Marrow Transplant. 2008 Sep 22.
Hart C, Grassinger J, Andreesen R, Hennemann B.
Department of Hematology and Oncology, Regensburg University Medical Center, Regensburg, Germany.
EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Vepesid review article...
|
|
Drugs to treat lung cancer
 Vepesid prescribing information
Buy here
|
|
My Basket
